Literature DB >> 15965037

Cost valuation in resource-poor settings.

Guy Hutton1, Rob Baltussen.   

Abstract

Methods of cost-effectiveness analysis (CEA) have largely been developed for application in Western country settings. Little attention has been paid to the methodological issues in cost valuation in resource-poor settings, where failing exchange rates and severe market distortions require further clarifications of appropriate valuation methods. This paper links insights from social cost-benefit analysis with the current CEA guidelines to develop a more apt approach to cost valuation in resource-poor settings.

Mesh:

Year:  2005        PMID: 15965037     DOI: 10.1093/heapol/czi025

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  20 in total

Review 1.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Cost-effectiveness of a district trauma hospital in Battambang, Cambodia.

Authors:  Richard A Gosselin; Merja Heitto
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

3.  Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?

Authors:  Baudouin Standaert; Olivier Ethgen; Rachel Emerson; Maarten Postma; Josephine Mauskopf
Journal:  Adv Ther       Date:  2014-10-21       Impact factor: 3.845

4.  The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.

Authors:  Lesong Conteh; Elisa Sicuri; Fatuma Manzi; Guy Hutton; Benson Obonyo; Fabrizio Tediosi; Prosper Biao; Paul Masika; Fred Matovu; Peter Otieno; Roly D Gosling; Mary Hamel; Frank O Odhiambo; Martin P Grobusch; Peter G Kremsner; Daniel Chandramohan; John J Aponte; Andrea Egan; David Schellenberg; Eusebio Macete; Laurence Slutsker; Robert D Newman; Pedro Alonso; Clara Menéndez; Marcel Tanner
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

5.  Basing care reforms on evidence: the Kenya health sector costing model.

Authors:  Steffen Flessa; Michael Moeller; Tim Ensor; Klaus Hornetz
Journal:  BMC Health Serv Res       Date:  2011-05-27       Impact factor: 2.655

6.  Cost-effectiveness of intermittent preventive treatment of malaria in infants (IPTi) for averting anaemia in Gabon: a comparison between intention to treat and according to protocol analyses.

Authors:  Elisa Sicuri; Prosper Biao; Guy Hutton; Fabrizio Tediosi; Clara Menendez; Bertrand Lell; Peter Kremsner; Lesong Conteh; Martin P Grobusch
Journal:  Malar J       Date:  2011-10-17       Impact factor: 2.979

7.  Improving the use of research evidence in guideline development: 11. Incorporating considerations of cost-effectiveness, affordability and resource implications.

Authors:  Tessa Tan-Torres Edejer
Journal:  Health Res Policy Syst       Date:  2006-12-05

8.  Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia.

Authors:  Kafula Silumbe; Joshua O Yukich; Busiku Hamainza; Adam Bennett; Duncan Earle; Mulakwa Kamuliwo; Richard W Steketee; Thomas P Eisele; John M Miller
Journal:  Malar J       Date:  2015-05-20       Impact factor: 2.979

9.  Collecting and analysing cost data for complex public health trials: reflections on practice.

Authors:  Neha Batura; Anni-Maria Pulkki-Brännström; Priya Agrawal; Archana Bagra; Hassan Haghparast-Bidgoli; Fiammetta Bozzani; Tim Colbourn; Giulia Greco; Tanvir Hossain; Rajesh Sinha; Bidur Thapa; Jolene Skordis-Worrall
Journal:  Glob Health Action       Date:  2014-02-18       Impact factor: 2.640

10.  Tracking rural health facility financial data in resource-limited settings: a case study from Rwanda.

Authors:  Chunling Lu; Sandy Tsai; John Ruhumuriza; Grace Umugiraneza; Solange Kandamutsa; Phillip P Salvatore; Zibiao Zhang; Agnes Binagwaho; Fidele Ngabo
Journal:  PLoS Med       Date:  2014-12-02       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.